A Phase 4 interventional study of Edaravone and Sodium Ozagrel in Cerebral Infarction, sponsored by Shionogi. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Shionogi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.
219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.
This study's enrollment of 401 is above the median of 120 across 139 interventional studies indexed under Cerebral Infarction.
Browse Cerebral Infarction studies →Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Edaravone
Drug: Sodium Ozagrel
Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.
Also known as: Radicut
Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.
the Rate of Patients With a Modified Rankin Scale Score of 0-1
The number of patients with mRS score of 0-1 (good outcome) at 3 months after treatment initiation. The mRS has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability.
Time frame: 3 months
Barthel Index Score
The Barthel Index of Activities of Daily Living measures functional disability by quantifying patient performance in 10 activities of daily life. These activities can be grouped according to self-care (feeding, grooming, bathing, dressing, bowel and bladder care, and toilet use) and mobility (ambulation, transfers, and stair climbing). 5-point increments are used in scoring, with a maximal score of 100 indicating that a patient is fully independent in physical functioning, and a lowest score of 0 representing a totally dependent bed-ridden state. The number of patients with 95-100 Barthel Index was evaluated at at 3 months after treatment initiation.
Time frame: 3 months
Baseline NIH Stroke Scale Score
The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead).
Time frame: Before treatment initiation
NIH Stroke Scale Score at 14 Days
The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 14 days after treatment initiation.
Time frame: 14 days
NIH Stroke Scale Score at 1 Month
The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 1 month after treatment initiation.
Time frame: 1 month
NIH Stroke Scale Score at 3 Months
The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 3 months after treatment initiation.
Time frame: 3 months
Japan Stroke Scale (Motor Function) Score at 14 Days
The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 14 days after treatment initiation.
Time frame: 14 days
Japan Stroke Scale (Motor Function) Score at 1 Month
The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 1 month after treatment initiation.
Time frame: 1 month
Japan Stroke Scale (Motor Function) Score at 3 Months
The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 3 months after treatment initiation.
Time frame: 3 months
Modified Rankin Scale Score
The number of patients with an Modified Rankin Scale score of 0-1 was evaluated at 6 months after treatment initiation. The Modified Rankin Scale has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability.
Time frame: 6 months
| Milestone | Edaravone | Ozagrel |
|---|---|---|
| Started | 199 | 202 |
| Safety analysis set | 194 | 198 |
| Completed | 191 | 195 |
| Not completed | 8 | 7 |
| Withdrew: Lack of efficacy | 3 | 3 |
| Withdrew: Protocol violation | 4 | 4 |
| Withdrew: Nontreatment | 1 | 0 |
The Barthel Index of Activities of Daily Living measures functional disability by quantifying patient performance in 10 activities of daily life. These activities can be grouped according to self-care (feeding, grooming, bathing, dressing, bowel and bladder care, and toilet use) and mobility (ambulation, transfers, and stair climbing). 5-point increments are used in scoring, with a maximal score of 100 indicating that a patient is fully independent in physical functioning, and a lowest score of 0 representing a totally dependent bed-ridden state. The number of patients with 95-100 Barthel Index was evaluated at at 3 months after treatment initiation.
| participants | Edaravone | Ozagrel |
|---|---|---|
| Barthel Index Score | 148 | 133 |
The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead).
| scores on a scale | Edaravone | Ozagrel |
|---|---|---|
| Baseline NIH Stroke Scale Score | 3.7 ± 2.3 | 3.8 ± 2.7 |
The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 14 days after treatment initiation.
| participants | Edaravone | Ozagrel |
|---|---|---|
| NIH Stroke Scale Score at 14 Days | 98 | 108 |
The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 1 month after treatment initiation.
| participants | Edaravone | Ozagrel |
|---|---|---|
| NIH Stroke Scale Score at 1 Month | 117 | 119 |
The number of patients with mRS score of 0-1 (good outcome) at 3 months after treatment initiation. The mRS has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability.
| participants | Edaravone | Ozagrel |
|---|---|---|
| Score(0-1) | 109 | 98 |
| 0 | 46 | 39 |
| 1 | 63 | 59 |
| 2 | 37 | 40 |
| 3 | 22 | 29 |
| 4 | 19 | 24 |
| 5 | 2 | 3 |
| Death | 2 | 1 |
The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 3 months after treatment initiation.
| participants | Edaravone | Ozagrel |
|---|---|---|
| NIH Stroke Scale Score at 3 Months | 135 | 140 |
The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 14 days after treatment initiation.
| units on a scale | Edaravone | Ozagrel |
|---|---|---|
| Japan Stroke Scale (Motor Function) Score at 14 Days | 4.521 ± 6.651 | 4.686 ± 6.872 |
The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 1 month after treatment initiation.
| units on a scale | Edaravone | Ozagrel |
|---|---|---|
| Japan Stroke Scale (Motor Function) Score at 1 Month | 3.632 ± 6.086 | 3.680 ± 5.885 |
The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 3 months after treatment initiation.
| units on a scale | Edaravone | Ozagrel |
|---|---|---|
| Japan Stroke Scale (Motor Function) Score at 3 Months | 2.507 ± 5.232 | 2.927 ± 5.361 |
The number of patients with an Modified Rankin Scale score of 0-1 was evaluated at 6 months after treatment initiation. The Modified Rankin Scale has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability.
| participants | Edaravone | Ozagrel |
|---|---|---|
| Modified Rankin Scale Score | 112 | 108 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Edaravone | — | 27/194 (13.9%) | 102/194 (52.6%) |
| Ozagrel | — | 28/198 (14.1%) | 107/198 (54%) |
| Event | Edaravone | Ozagrel |
|---|---|---|
| Cerebral infarctionNervous system disorders | 5/194 | 11/198 |
| IleusGastrointestinal disorders | 2/194 | 0/198 |
| PneumoniaInfections and infestations | 2/194 | 1/198 |
| Transient ischemic attackNervous system disorders | 2/194 | 0/198 |
| HemiplegiaNervous system disorders | 0/194 | 2/198 |
| Anastomotic ulcer haemorrhageInjury, poisoning and procedural complications | 1/194 | 0/198 |
| Angina pectorisCardiac disorders | 1/194 | 0/198 |
| Anti-neutrophil cytoplasmic antibody positive vasculitisImmune system disorders | 1/194 | 0/198 |
| ArrhythmiaCardiac disorders | 1/194 | 0/198 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/194 | 0/198 |
| Event | Edaravone | Ozagrel |
|---|---|---|
| ConstipationGastrointestinal disorders | 59/194 | 64/198 |
| InsomniaPsychiatric disorders | 24/194 | 33/198 |
| NasopharyngitisInfections and infestations | 19/194 | 13/198 |
| Back painMusculoskeletal and connective tissue disorders | 11/194 | 17/198 |
| HeadacheNervous system disorders | 11/194 | 12/198 |
| Urinary tract infectionInfections and infestations | 9/194 | 11/198 |
| DiarrheaGastrointestinal disorders | 10/194 | 6/198 |
| PruritusSkin and subcutaneous tissue disorders | 9/194 | 10/198 |
| Age, Customized(years) | Edaravone | Ozagrel | Total |
|---|---|---|---|
| birth-19 years | 0 | 0 | 0 |
| 20-64 years | 64 | 58 | 122 |
| 65- years | 127 | 137 | 264 |
| Sex: Female, Male(Participants) | Edaravone | Ozagrel | Total |
|---|---|---|---|
| Female | 70 | 77 | 147 |
| Male | 121 | 118 | 239 |
No study locations are listed for this record.
Ran from Aug 2004 to primary completion in Oct 2006, 26 months.
Results were first posted in Jan 2013, 6 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edaravone